Vescor, advised by its scientific founders White and Kimmelman, whose research has shown inhibition of autophagy can dramatically impact tumor growth in pre-clinical models, will develop small
molecule inhibitors of a number of protein targets
at critical
nodes of the autophagy cascade, perform investigational new drug (IND) enabling studies, and move these into clinical development.